{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:34:37Z","timestamp":1792708477934,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Rare diseases, affecting millions globally, pose a significant healthcare burden despite impacting a small population. While approximately 70% of all rare diseases are genetic and often begin in childhood, diagnosis remains slow and only 5% have approved treatments. The UN emphasizes improved access to primary care (diagnostic and potentially therapeutic) for these patients and their families. Next-generation sequencing (NGS) offers hope for earlier and more accurate diagnoses, potentially leading to preventative measures and targeted therapies. In here, we explore the therapeutic landscape for rare diseases, analyzing drugs in development and those already approved by the European Medicines Agency (EMA). We differentiate between orphan drugs with market exclusivity and repurposed existing drugs, both crucial for patients. By analyzing market size, segmentation, and publicly available data, this comprehensive study aims to pave the way for improved understanding of the treatment landscape and a wider knowledge accessibility for rare disease patients.<\/jats:p>","DOI":"10.3389\/fpubh.2025.1520467","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T01:37:15Z","timestamp":1738546635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Quantifying hope: an EU perspective of rare disease therapeutic space and market dynamics"],"prefix":"10.3389","volume":"13","author":[{"given":"Emmanuelle","family":"Cacoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie Barreto","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrije","family":"Milunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2214-109X(24)00056-1","article-title":"The landscape for rare diseases in 2024","volume":"12","year":"2024","journal-title":"Lancet Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41431-021-00882-1","article-title":"Toward the diagnosis of rare childhood genetic diseases: what do parents value most?","volume":"29","author":"Pollard","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"ref3","year":""},{"key":"ref4","volume-title":"What is a rare disease?","year":""},{"key":"ref5","volume-title":"UN resolution on persons living with a rare disease and their families","year":""},{"key":"ref6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/cells13060504","article-title":"Implementing whole genome sequencing (WGS) in clinical practice: advantages, challenges, and future perspectives","volume":"13","author":"Brlek","year":"2024","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ajmg.c.32017","article-title":"Whole-genome sequencing holds the key to the success of gene-targeted therapies","volume":"193","author":"Vockley","year":"2023","journal-title":"Am J Med Genet C: Semin Med Genet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1249585","DOI":"10.3389\/fgene.2023.1249585","article-title":"Editorial: next generation sequencing (NGS) for rare diseases diagnosis - volume II","volume":"14","author":"Yang","year":"2023","journal-title":"Front Genet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1474-4422(21)00462-2","article-title":"Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study","volume":"21","author":"Iba\u00f1ez","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41591-023-02401-9","article-title":"Integrated multi-omics for rapid rare disease diagnosis on a national scale","volume":"29","author":"Lunke","year":"2023","journal-title":"Nat Med"},{"key":"ref11","year":""},{"key":"ref12","volume-title":"World\u2019s most expensive drug is now $4.25 million gene therapy","year":"2024"},{"key":"ref13","volume-title":"Despite eye-popping $3.5 million Price tag for gene therapy Hemgenix, budget impact for Most payers will be relatively small","author":"Cohen","year":""},{"key":"ref14","volume-title":"The most expensive drug in the US is a rare-disease game changer\u2014bloomberg","year":""},{"key":"ref15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13023-022-02407-5","article-title":"Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs","volume":"17","author":"Brandt","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","year":"2024"},{"key":"ref17","year":""},{"key":"ref18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/iep.12478","article-title":"Clinical applications of gene therapy for rare diseases: a review","volume":"104","author":"Papaioannou","year":"2023","journal-title":"Int J Exp Pathol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"102201","DOI":"10.1016\/j.coph.2022.102201","article-title":"Precision medicine for rare diseases: the times they are A-Changin","volume":"63","author":"Amaral","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13023-024-03162-5","article-title":"Landscape analysis of available European data sources amenable for machine learning and recommendations on usability for rare diseases screening","volume":"19","author":"Raycheva","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1016\/j.ymthe.2023.09.020","article-title":"The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for orphan medicinal products","volume":"31","author":"Palomo","year":"2023","journal-title":"Mol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"D552","DOI":"10.1093\/nar\/gkp937","article-title":"STITCH 2: an interaction network database for small molecules and proteins","volume":"38","author":"Kuhn","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"ref24","volume-title":"Sales share from orphan drug by top companies 2028 forecast","year":""},{"key":"ref25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41597-021-00905-y","article-title":"A resource to explore the discovery of rare diseases and their causative genes","volume":"8","author":"Ehrhart","year":"2021","journal-title":"Sci Data"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2174\/0929867328666210526144654","article-title":"Enzyme replacement therapy for genetic disorders associated with enzyme deficiency","volume":"29","author":"Marchetti","year":"2022","journal-title":"Curr Med Chem"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/11875","article-title":"Gene therapy for rare diseases","volume":"22","year":"1999","journal-title":"Nat Genet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"100530","DOI":"10.1016\/j.xcrm.2022.100530","article-title":"Why rare disease needs precision medicine\u2014and precision medicine needs rare disease","volume":"3","author":"Might","year":"2022","journal-title":"Cell Rep Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"D684","DOI":"10.1093\/nar\/gkm795","article-title":"STITCH: interaction networks of chemicals and proteins","volume":"36","author":"Kuhn","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases8040042","article-title":"Precision medicine in rare diseases","volume":"8","author":"Villal\u00f3n-Garc\u00eda","year":"2020","journal-title":"Diseases"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.fertnstert.2018.05.006","article-title":"Personalized medicine: motivation, challenges, and progress","volume":"109","author":"Goetz","year":"2018","journal-title":"Fertil Steril"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-022-00636-2","article-title":"Advances in CRISPR therapeutics","volume":"19","author":"Chavez","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.3390\/life12121968","article-title":"CRISPR-based tools for fighting rare diseases","volume":"12","author":"Li","year":"2022","journal-title":"Life"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40291-019-00392-3","article-title":"Rare opportunities: CRISPR\/Cas-based therapy development for rare genetic diseases","volume":"23","author":"Papasavva","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"809118","DOI":"10.3389\/fmed.2021.809118","article-title":"Gene therapy advances: a Meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2022","journal-title":"Front Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/21678707.2015.1039511","article-title":"Recombinant adeno-associated virus vectors in the treatment of rare diseases","volume":"3","author":"Hastie","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/hum.2024.022","article-title":"Development of AAV-mediated gene therapy approaches to treat skeletal diseases","volume":"35","author":"Lin","year":"2024","journal-title":"Hum Gene Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-024-07310-6","article-title":"Antisense oligonucleotide therapeutic approach for Timothy syndrome","volume":"628","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/cts.13619","article-title":"Artificial intelligence in rare disease diagnosis and treatment","volume":"16","author":"Wojtara","year":"2023","journal-title":"Clin Transl Sci"},{"key":"ref42","volume-title":"Every life Foundation for Rare Diseases","year":""},{"key":"ref43","year":""},{"key":"ref44","volume-title":"Rare diseases international","year":"2024"},{"key":"ref45","year":""},{"key":"ref46","year":""},{"key":"ref47","year":"2022"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"116332","DOI":"10.1016\/j.socscimed.2023.116332","article-title":"The role of patient organisations in research and development: evidence from rare diseases","volume":"338","author":"Gentilini","year":"2023","journal-title":"Soc Sci Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"15174","DOI":"10.3390\/ijerph192215174","article-title":"Health policies for rare disease patients: a scoping review","volume":"19","author":"Lopes-J\u00fanior","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e039473","DOI":"10.1136\/bmjopen-2020-039473","article-title":"Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations","volume":"10","author":"Roennow","year":"2020","journal-title":"BMJ Open"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1520467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T01:37:22Z","timestamp":1738546642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1520467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":50,"alternative-id":["10.3389\/fpubh.2025.1520467"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1520467","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.21.24310776","asserted-by":"object"}]},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"article-number":"1520467"}}